1-15 of 15
Loretta J. Nastoupil, MD
Close
Sort by
Articles

Health Equity: Are We Missing the Mark With CAR T-cell Therapy?

Loretta J. Nastoupil, MD
Journal: The Hematologist
The Hematologist (2024) 21 (4)
https://doi.org/10.1182/hem.V21.4.2024411
Published: 2024
Articles

Sequencing of Therapy Matters in the Era of Autologous Chimeric Antigen Receptor T-cell Therapy

Karan L. Chohan, MD, Loretta J. Nastoupil, MD
Journal: The Hematologist
The Hematologist (2024) 21 (3)
https://doi.org/10.1182/hem.V21.3.202438
Published: 2024
Articles

Do Bispecific Antibodies Open the Door to Novel–novel Combinations for Patients With Relapsed/Refractory Large B-cell Lymphoma?

Loretta J. Nastoupil, MD
Journal: The Hematologist
The Hematologist (2024) 21 (2)
https://doi.org/10.1182/hem.V21.2.202424
Published: 2024
Articles

Pola-R-CHP: A Dramatic Shift in the Frontline Treatment Paradigm for Diffuse Large B-cell Lymphoma, or a Small Step Forward?

Neha Akkad, MD, Loretta J. Nastoupil, MD
Journal: The Hematologist
The Hematologist (2024) 21 (1)
https://doi.org/10.1182/hem.V21.1.202418
Published: 2024
Articles

MAHOGANY: Will it Establish Zanbrutinib, a Second-generation Bruton Tyrosine Kinase Inhibitor, as a Preferred Targeted Therapy for Relapsed/Refractory Follicular and Marginal Zone Lymphomas?

Loretta J. Nastoupil, MD
Journal: The Hematologist
The Hematologist (2023) 20 (6)
https://doi.org/10.1182/hem.V20.6.202369
Published: 2023
Articles

Moving On Up: Second-line Axicabtagene Ciloleucel Improves Overall Survival in Patients With LBCL

Dustin B. McCurry, MD, Loretta J. Nastoupil, MD
Journal: The Hematologist
The Hematologist (2023) 20 (5)
https://doi.org/10.1182/hem.V20.5.2023511
Published: 2023
Articles

Will CAR T-Cell Therapy Be the Preferred Modality in Frontline Treatment of Large B-Cell Lymphoma?

Loretta J. Nastoupil, MD
Journal: The Hematologist
The Hematologist (2023) 20 (4)
https://doi.org/10.1182/hem.V20.4.2023414
Published: 2023
Articles

The Yin and Yang of CAR T-cell Therapy: Lessons to Be Learned from Noninvasive Profiling

Loretta J. Nastoupil, MD
Journal: The Hematologist
The Hematologist (2023) 20 (3)
https://doi.org/10.1182/hem.V20.3.202334
Published: 2023
Articles

The Next Wave of T-cell Engagement for the Management of Diffuse Large B-cell Lymphoma

Loretta J. Nastoupil, MD
Journal: The Hematologist
The Hematologist (2023) 20 (2)
https://doi.org/10.1182/hem.V20.2.202324
Published: 2023
Articles

CAR T-cell Therapy: A Major Shift in the Treatment Landscape for Early-Relapse Aggressive B-Cell Lymphomas

Chijioke Nze, MD, MPH, Loretta J. Nastoupil, MD
Journal: The Hematologist
The Hematologist (2023) 20 (1)
https://doi.org/10.1182/hem.V20.1.202318
Published: 2023
Articles

CELESTIMO: A Randomized Phase III Trial Examining the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide Versus Rituximab in Combination With Lenalidomide in Relapsed/Refractory Follicular Lymphoma

Loretta J. Nastoupil, MD
Journal: The Hematologist
The Hematologist (2022) 19 (6)
https://doi.org/10.1182/hem.V19.6.2022610
Published: 2022
Articles

Shining a Light on a Randomized Trial: Ibrutinib Plus Rituximab and Bendamustine in Untreated Mantle Cell Lymphoma

Loretta J. Nastoupil, MD
Journal: The Hematologist
The Hematologist (2022) 19 (5)
https://doi.org/10.1182/hem.V19.5.202258
Published: 2022
Articles

Trust Your Gut: Changes in Intestinal Microbiome Are Associated With Outcomes Following CAR-T Therapy

Loretta J. Nastoupil, MD
Journal: The Hematologist
The Hematologist (2022) 19 (4)
https://doi.org/10.1182/hem.V19.4.202247
Published: 2022
Articles

POLARIX: Is R-CHOP in the Rearview Mirror?

Loretta J. Nastoupil, MD
Journal: The Hematologist
The Hematologist (2022) 19 (3)
https://doi.org/10.1182/hem.V19.3.202235
Published: 2022
Articles

Navigating the Treatment Landscape of Advanced Follicular Lymphoma: Should You Consider a CAR, and Which Model?

Loretta J. Nastoupil, MD
Journal: The Hematologist
The Hematologist (2022) 19 (2)
https://doi.org/10.1182/hem.V19.2.202226
Published: 2022